Top stories: CPRIT doles out $22M to Houston institutions, brainy new AI tech, and more

what's trending?

CPRIT doled out fresh funding to Houston institutions — and more trending innovation news in Houston. Photo via tmc.edu

Editor's note: Let's roundup the most-read Houston innovation news from the week. Trending Houston tech and startup articles from InnovationMap and its daily newsletter included fresh funding from CPRIT, a health tech startup's series A, and more.

Houston health care institutions receive $22M to attract top recruits

The grants, which are between $2 million to $6 million each, are earmarked for recruitment of prominent researchers. Photo via Getty Images

Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.

The two grants, which are $6 million each, are earmarked for recruitment of Thomas Milner and Radek Skoda. The Cancer Prevention & Research Institute of Texas (CPRIT) announced the grants May 14. Continue reading.

Houston startup secures $10M to expand into rural communities

Dr. Toby Hamilton has secured $10 million to grow his company. Photo via tmc.edu

A Houston company that is working on a value-based model for primary care has fresh funding to support its mission.

Hamilton Health Box announced the completion of a $10 million series A funding round led by 1588 Ventures with participation from Memorial Hermann Health System, Impact Ventures by Johnson & Johnson Foundation, Texas Medical Center Venture Fund, and the Sullivan Brothers.

Founded in 2019 by Dr. Toby R. Hamilton, the company will use the funding to fuel its expansion into rural areas to help assist those living in Health Professional Shortage Areas, or HPSAs. Continue reading.

Houston researchers create AI model to tap into how brain activity relates to illness

BrainLM is now well-trained enough to use to fine-tune a specific task and to ask questions in other studies. Photo via Getty Images

Houston researchers are part of a team that has created an AI model intended to understand how brain activity relates to behavior and illness.

Scientists from Baylor College of Medicine worked with peers from Yale University, University of Southern California and Idaho State University to make Brain Language Model, or BrainLM. Their research was published as a conference paper at ICLR 2024, a meeting of some of deep learning’s greatest minds.

“For a long time we’ve known that brain activity is related to a person’s behavior and to a lot of illnesses like seizures or Parkinson’s,” Dr. Chadi Abdallah, associate professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor and co-corresponding author of the paper, says. Continue reading.

Houston family's $20M donation drives neurodegeneration research

The Belfer family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium. Photo via mdanderson.org

Neurodegeneration is one of the cruelest ways to age, but one Houston family is sharing its wealth to invigorate research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer. Continue reading.

Booming Houston suburb, other Texas towns among the fastest-growing U.S. cities in 2023

Here's how Texas towns stacked up on a new population report. Photo via Getty Images

One Houston suburb experienced one of the most rapid growth spurts in the country last year: Fulshear, whose population grew by 25.6 percent, more than 51 times that of the nation’s growth rate of 0.5 percent. The city's population was 42,616 as of July 1, 2023.

According to U.S. Census Bureau's Vintage 2023 Population Estimates, released Thursday, May 16, Fulshear — which lies west of Katy in northwest Fort Bend County - ranked No. 2 on the list of fastest-growing cities with a population of 20,000 or more. It's no wonder iconic Houston restaurants like Molina's Cantina see opportunities there.

The South still dominates the nation's growth, even as America’s Northeast and Midwest cities are rebounding slightly from years of population drops. The census estimates showed 13 of the 15 fastest-growing cities in the U.S. were in the South — eight in Texas alone. Continue reading.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

CardioOne, which built a physician enablement platform for independent cardiologists, has been acquired by WindRose Health Investors. Photo via cardioone.com

Houston cardiology-focused tech platform exits to private equity, plans to scale

making moves

A Houston health tech startup founded only last year has exited to a New York private equity firm.

CardioOne, which built a physician enablement platform for independent cardiologists, has been acquired by WindRose Health Investors. The complete terms of the deal were not disclosed, but according to a WindRose news release, the firm will provide up to $100 million of additional capital to go toward supporting CardioOne's growth.

The fresh influx of capital will go toward expanding and enhancing existing service options. The CardioOne leadership team will continue to be at the helm of the startup.

"We are excited for the opportunity to partner with WindRose as CardioOne embarks on its next chapter of growth," Dr. Jasen Gundersen, CardioOne's CEO and co-founder, says in the release. "We believe that working with WindRose, which has a history of successfully partnering with companies to help navigate the transition to value-based care, will empower us to continue supporting independent cardiologists while developing additional solutions that maximize each practice's potential in the shift to VBC arrangements."

Last year, CardioOne raised an $8 million seed round and announced key partnerships at clinics in New Jersey, Florida, and Pennsylvania, in addition to existing relationships in Texas and Maryland. CardioOne also partnered with MedAxiom, an organizational performance solutions provider in the industry.

"CardioOne's unique, physician-aligned model meets the market where it is and positions the Company to take advantage of the growing desire among cardiologists to maintain their independence," Oliver Moses, managing partner with WindRose, adds. "We believe CardioOne delivers a compelling tech-enabled offering to the independent cardiology market and has significant growth potential as the Company builds upon its momentum in 2023. We are excited to join forces with Jasen and his team as they continue to build upon the differentiated platform they have created."

Rosarium Health, a member of the Texas Medical Center's 2023 Accelerator for HealthTech cohort, has raised pre-seed funding. Photo courtesy of TMC

Health tech startup raises $1.7M, plans Houston HQ

eyes on hou

A health tech startup that just collected $1.7 million in pre-seed funding aims to eventually plant its headquarters in Houston.

The startup, Rosarium Health, currently has no headquarters; its 10 employees work remotely from various locations. However, co-founder and CEO Cameron Carter — who lives in the Denver area — says the company is eyeing a future headquarters in Houston.

“We believe Houston is the best city to launch a health care startup, given the Texas Medical Center, diverse talent across health and technology, affordable living, and a city with supportive and progressive communities,” Carter tells InnovationMap. “We feel Houston offers meaningful attributes that can enable a high-growth startup to succeed and for its employees to feel safe.”

Rosarium, founded in 2021 as Rose Health, is a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. Last year, the company received $60,000 as a winner in the National Institute on Aging’s Healthy Aging Start-Up Challenge and Bootcamp, designed to foster diversity and innovation.

Rosarium’s AI-powered platform connects home contractors and occupational therapists with clients to carry out accessibility projects in households occupied by seniors and people with disabilities. The startup launched its offering in the Houston area with a focus on multigenerational households.

“Our homes are our sanctuaries, but for people with mobility issues, inaccessible spaces can cause frustration, unsafe living conditions, and a loss of dignity,” Carter says in a news release. “Interest in creating accessible living spaces is growing among everyday people, service providers, and professional investors.”

Carter says the $1.7 million in new funding will enable his company to add employees as it seeks to broaden its reach in Texas and expand to other states. The money also will help efforts to recruit bilingual and trilingual contractors.

Primetime Partners and Rock Health Capital led the round, with participation from Tundra Ventures, Flare Capital Partners, Sequential Ventures, Groundbreak Ventures, and several angel investors.

“We will begin developing our enterprise product with a goal to partner with health plans and accountable care organizations in 2024,” he says.

Carter has worked in the health care industry since 2014. Joseph Akoni, Rosarium’s co-founder and chief product officer, has a background in product management.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.

View All Listings